Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV/IP Paclitaxel/Carboplatin and Radiation in Advanced Uterine Serous Carcinoma
NCT04030000Phase 2Withdrawn
- Sponsor
- Northwell Health
- Start
- May 2020
- Primary completion
- Aug 2022
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection and carboplatin in uterine serous carcinoma (USC), sponsored by Northwell Health. Primary endpoints: Incidence of Treatment-related Adverse Events and Feasibility of regimen. Planned start May 2020; status: withdrawn.
02
Drugs
Paclitaxel Micelles for Injectioncarboplatin
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT04030000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030000.